List of Excipients in API fostamatinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing fostamatinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | FERRIC OXIDE RED | 2032-07-27 |
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | FERRIC OXIDE YELLOW | 2032-07-27 |
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | MAGNESIUM STEARATE | 2032-07-27 |
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | MANNITOL | 2032-07-27 |
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | POLYETHYLENE GLYCOL 3350 | 2032-07-27 |
| Rigel Pharmaceuticals Inc | TAVALISSE | fostamatinib | 71332-001 | POLYVINYL ALCOHOL | 2032-07-27 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for fostamatinib
Excipient focus: FERRIC OXIDE RED
fostamatinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
fostamatinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
fostamatinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
fostamatinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
fostamatinib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
fostamatinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
fostamatinib drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BICARBONATE
fostamatinib drug variants containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing SODIUM BICARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
fostamatinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
fostamatinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
fostamatinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Rigel Pharmaceuticals Inc | fostamatinib | 71332-001 |
| >Company | >Ingredient | >NDC |
fostamatinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch